FDA Approves Symvess, an Acellular Tissue-Engineered Vessel
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 2, 2025 -- The U.S. Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to prevent imminent limb loss.
Symvess is a sterile, acellular tissue-engineered vessel composed of extracellular matrix proteins usually found in human blood vessels and is manufactured using human vascular smooth muscle cells derived from human aortic tissue. The one-time, single-use product is implanted surgically to replace a patient's damaged blood vessel after traumatic injury to the extremity.
The safety and effectiveness of Symvess was assessed in a prospective, single-arm, multicenter study involving 54 patients with life- or limb-threatening vascular trauma. Of the 54 patients, 36 (67 percent) and 39 patients (72 percent), respectively, retained primary patency (blood flow present without any intervention) and secondary patency (at least one intervention required to maintain blood flow) at 30 days after implantation. Five and eight patients underwent amputation of the treated limb within the first 30 days and by the end of study (month 36), respectively.
"Today's decision to approve a new therapeutic product based on novel medical technology represents important progress in addressing a significant unmet medical need," Nicole Verdun, M.D., director of the Office of Therapeutic Products in the FDA Center for Biologics Evaluation and Research, said in a statement.
Approval of Symvess was granted to Humacyte Global.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Pediatric Magnet Ingestion Rates Still High
THURSDAY, May 22, 2025 -- Global pediatric magnet ingestion rates remain high and incidence has increased, despite the implementation of national policies, according to a review...
Similar Survival Seen With Simple Versus Radical Hysterectomy for Cervical Cancer
WEDNESDAY, May 21, 2025 -- For patients with low-risk cervical cancer, survival is similar following simple hysterectomy (SH) versus modified radical hysterectomy (MRH) or radical...
Stereotactic Body Radiotherapy Feasible After Radical Prostatectomy
TUESDAY, May 20, 2025 -- Post-radical prostatectomy (post-RP) stereotactic body radiotherapy (SBRT) is well tolerated, with patient-reported outcomes (PROs) comparable to those...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.